CN105902554A - Method for preparing a medicament for treating cerebrovascular diseases - Google Patents
Method for preparing a medicament for treating cerebrovascular diseases Download PDFInfo
- Publication number
- CN105902554A CN105902554A CN201610327364.XA CN201610327364A CN105902554A CN 105902554 A CN105902554 A CN 105902554A CN 201610327364 A CN201610327364 A CN 201610327364A CN 105902554 A CN105902554 A CN 105902554A
- Authority
- CN
- China
- Prior art keywords
- cerebrovascular disease
- method preparing
- preparing treatment
- treatment cerebrovascular
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/20—General preparatory processes
- C08G64/38—General preparatory processes using other monomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a method for preparing a medicament for treating cerebrovascular diseases. The method comprises the steps of preparing a polycarbonate and a dispersion medium, and dispersing an active medicament into the medium under compatibilization of the polycarbonate to obtain a treatment medicament suspended uniformly, wherein the active ingredient can be an existing medicament, such as ginsenoside Rd. Medicament study results show that the medicament can form a uniform suspension so as to solve the problem that the existing ginsenoside Rd can produce hemolysis, and can be used for treating cerebrovascular diseases.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to a kind of side preparing treatment cerebrovascular disease medicine
Method.
Background technology
The biodegradable polymer of synthesis is owing to its immunogenicity is relatively low, its performance contains such as degradation property and machine
Tool performances etc. all can conveniently obtain controlling to wait and be particularly subject to pay close attention to.Wherein, the most poly-three methylenes of Merlon
Basic ring carbonic ester and aliphatic polyester such as PGA, polylactide, PLGA etc. are
The most frequently used biodegradable polymer, has obtained the license of U.S. food Drug Administration (FDA).
Along with social progress, living standard raising and aged tendency of population, cerebrovascular disease morbidity is day by day young
Changing, human health and life security in serious threat.Therefore, cerebrovascular disease protective agents tool is developed
It is of great significance.Cerebrovascular disease includes that cerebral ischemia, cerebral hemorrhage, cerebral anoxia, vascular are crazy about
Staying, cerebral ischemia refers to one group of disease of brain function disappearance caused by blood supply insufficiency；Cerebral anoxia refers to brain
All kinds of symptoms that oxygen supply is not enough and occurs；Vascular dementia refers in ischemic, hemorrhagic and urgency
On the basis of the brain tissue impairment that chronic ischemia Hypoxic cerebrovascular disease causes, generation with higher nerve
Cognitive dysfunction is one group of main clinical syndrome.Radix Ginseng is commonly used for treating effectively invigorating blood circulation of apoplexy
Blood stasis dispelling medicine, the composition to Radix Ginseng has carried out a wide range of research in recent years, and separated go out as effectively becoming
The different types of Saponin divided, in these Total saponin, ginsenoside-rd belongs to the master that Radix Ginseng is invigorated blood circulation
Want active ingredient, there is the usefulness of drug for invigorating blood circulation and eliminating stasis and be efficiently used for treating apoplexy.Injection excellent
Point is that bioavailability is high, rapid-action, it is adaptable to emergency and severe disease patient；But what injection the most often occurred asks
Topic is, produces uneven precipitation of dispersion etc..Improper mainly due to preparation technology, and preparation technology
All there is direct relation with the selection of pharmaceutical necessities.It is thus desirable to research and develop novel drug system, to obtain
Obtain suspendible and treat the medicine of cerebrovascular disease uniformly.
Summary of the invention
The goal of the invention of the present invention is to provide the preparation method of a kind of medication medication, the medicine prepared according to it
Objects system can be used for the treatment of cerebrovascular disease.
To achieve the above object of the invention, the technical solution used in the present invention is:
A kind of method preparing treatment cerebrovascular disease medicine, comprises the following steps,
(1) with pentadacanolide and third heptalactone as monomer, carbonate polymer is prepared in polymerization；
(2) mixed phosphate salt buffer, glycol monoethyl ether, water obtain disperse medium；
(3) carbonate polymer is added in disperse medium, be stirring evenly and then adding into ginsenoside Rd；
After ultrasonic disperse half an hour, sterilizing, obtain preparation treatment cerebrovascular disease medicine.
In the present invention, in step (1), using organic zinc compound as catalyst, different with azo two
Butyronitrile is as oxidant, using methylpentynol as initiator.
In the present invention, in a nitrogen environment, pentadacanolide and third heptalactone are molten in organic solvent,
Adding initiator and catalyst after stirring, stirring is subsequently adding oxidant, seals and carries out polyreaction,
Obtain carbonate polymer.Wherein, the mass ratio of described pentadacanolide and third heptalactone be 0.3～
0.5∶1；Polymeric reaction temperature is 45 DEG C, and polymerization time is 28 hours；Preferably organic solvent is
Dichloromethane；Catalyst is double (double trimethyls are silica-based) amine zinc.
It is further preferred that reaction terminates, terminate reaction with glacial acetic acid, precipitate in ice ether, mistake
Filter, vacuum drying obtain carbonate polymer.
In the present invention, in step (2), the percent by volume of described glycol monoethyl ether be 1.2～
2.4%；In step (3), ginsenoside Rd is 0.01～0.05 with the mass ratio of carbonate polymer:
1；Preferably ginsenoside Rd is 0.02～0.03: 1 with the mass ratio of carbonate polymer.
In the present invention, embody therapeutical effect using active component ginsenoside Rd as medicine main group
Become, using pharmaceutical carrier carbonate polymer as increase-volume medicine, improve the dispersibility of medicine, with mixed
Outstanding composition is as the scattered medium of medicine.Carbonate polymer hydrophobe segment distribution prepared by the present invention
Rationally, particularly add organic oxygen compound and can be effectively increased two monomer random copolymerization degree, be conducive to
Increase the compatibility of polymer and suspendible composition, such that it is able to improve active constituents of medicine in whole system
In dispersibility, it is to avoid occur be administered haemolysis.
The adjuvant of the present invention is pharmaceutically acceptable carrier.In this application, pharmaceutical carrier and mixed
Outstanding composition for being delivered to the internal of mammal (such as people) by pharmaceutical active compounds, it is therefore an objective to
Promote the absorption of the administration of organism, beneficially active component and then play therapeutic activity.
The pharmaceutically acceptable biological activity referring to not affect the compounds of this invention or the material of character
(such as carrier or diluent), and relative nontoxic, i.e. this material can be applied to individuality and not cause not
Good biological respinse or interact with any component comprised in bad mode and compositions.The present invention
Can also include but not limited to the license of any government administration section being correlated with for acceptable for the mankind or
The adjuvant of domestic animal use, carrier, excipient, fluidizer, sweetener, diluent, preservative, dye
Material/coloring agent, correctives, surfactant, wetting agent, dispersant, suspending agent, stabilizer,
Isotonic agent, solvent or emulsifying agent.
In medicine disclosed by the invention, by the compatibilization of carbonate polymer, work is greatly improved
Property medicine dispersibility in disperse medium, find through embodiment, it can resist cerebral infarction to be formed,
Such that it is able to become the medicine for the treatment of cerebrovascular disease.
Detailed description of the invention
The definition to the standard chemistry terms that the present invention records can be found in list of references.Unless otherwise
Illustrate, otherwise use the conventional method in the range of art technology, such as mass spectrum, NMR, IR and UV/VIS
Spectrographic method and pharmacological method.Unless proposed to be specifically defined, otherwise herein at analytical chemistry, You Jihe
It is known in the art for becoming chemistry and medicine and the pharmaceutical chemical term about using in describing.Can
Prepare at chemosynthesis, chemical analysis, medicine, preparation and delivery, and make in the treatment of patient
Use standard technique.Such as, according to the explanation of mode well known in the art or the present invention implement reaction and
It is purified.Generally can be according to the multiple summary quoted in this specification and discuss and more specific literary composition
Description in offering, implements above-mentioned technology and method according to conventional method well known in the art.
Effective dose, therapeutically effective amount or pharmacy effective dose refer to take metapedes to alleviate to a certain extent
The disease treated or at least one medicament of one or more symptoms of disease or the amount of compound.Its
Result can be abatement and/or the alleviation of sign, symptom or the cause of disease, or biosystem any other
Required change.Such as, the effective dose for treatment is to provide significant remission effect clinically
The amount of the required compositions comprising compound disclosed herein.The skill of such as dose escalation trial can be used
Art measures the effective dose being suitable in any individual case.
Take, use, administration etc. refers to be delivered to carry out biological agent by compound or compositions
The method in required site.These methods include but not limited to oral route, through intraduodenal routes,
Parental injection (including intravenous, subcutaneous, intraperitoneal, intramuscular, intra-arterial injection or infusion),
Topical and per rectum are administered, and can be used for compound described herein and side known to those skilled in the art
The application technique of method；In the preferred embodiment of the invention, medicine is by Orally administered.
Below in conjunction with specific embodiment, the present invention is expanded on further.It should be understood that, these embodiments only use
In the explanation present invention rather than restriction the scope of the present invention.Unreceipted actual conditions in the following example
Experimental technique, generally according to normal condition or according to the condition proposed by manufacturer；Unless it is another
External declaration, otherwise percentage ratio and number are percentage by weight and parts by weight.
The chemical structural formula of the compound that the present embodiment relates to is as follows:
Ginsenoside Rd
Third heptalactone
Pentadacanolide
Methylpentynol
Embodiment one
In a nitrogen environment, third heptalactone of 0.1g and 0.05g pentadacanolide are dissolved in 5mL dichloro
In methane, after stirring, add 0.04g3-methyl-1-pentene alkynes-3-alcohol and the catalyst of 0.1mol/L
The dichloromethane solution 100mL of double (double trimethyls are silica-based) amine zinc, stirring is subsequently adding 0.001g
Azodiisobutyronitrile, is sealed in 45 DEG C and reacts 28 hours, terminate reaction with glacial acetic acid, at ice ether
Middle precipitation, filters, is vacuum dried and obtains carbonate polymer.
Mixing 7mL phosphate buffer, 2.4mL glycol monoethyl ether, 0.6mL water, then by 0.1g
Carbonate polymer disperses wherein, stirs, and is eventually adding 5mg ginsenoside Rd, ultrasonic point
After dissipating half an hour, sterilizing, obtain medicine.
Embodiment two
In a nitrogen environment, third heptalactone of 0.1g and 0.03g pentadacanolide are dissolved in 5mL dichloro
In methane, after stirring, add 0.05g3-methyl-1-pentene alkynes-3-alcohol and the catalyst of 0.1mol/L
The dichloromethane solution 100mL of double (double trimethyls are silica-based) amine zinc, stirring is subsequently adding 0.001g
Azodiisobutyronitrile, is sealed in 45 DEG C and reacts 28 hours, terminate reaction with glacial acetic acid, at ice ether
Middle precipitation, filters, is vacuum dried and obtains carbonate polymer.
Mixing 6mL phosphate buffer, 1.2mL glycol monoethyl ether, 2.8mL water, then by 0.1g
Carbonate polymer disperses wherein, stirs, and is eventually adding 1mg ginsenoside Rd, ultrasonic point
After dissipating half an hour, sterilizing, obtain medicine.
Embodiment three
In a nitrogen environment, third heptalactone of 0.1g and 0.05g pentadacanolide are dissolved in 5mL dichloro
In methane, after stirring, add 0.04g3-methyl-1-pentene alkynes-3-alcohol and the catalyst of 0.1mol/L
The dichloromethane solution 100mL of double (double trimethyls are silica-based) amine zinc, stirring is subsequently adding 0.001g
Azodiisobutyronitrile, is sealed in 45 DEG C and reacts 28 hours, terminate reaction with glacial acetic acid, at ice ether
Middle precipitation, filters, is vacuum dried and obtains carbonate polymer.
Mixing 6mL phosphate buffer, 1.2mL glycol monoethyl ether, 2.8mL water, then by 0.1g
Carbonate polymer disperses wherein, stirs, and is eventually adding 1mg ginsenoside Rd, ultrasonic point
After dissipating half an hour, sterilizing, obtain medicine.
Embodiment four
In a nitrogen environment, third heptalactone of 0.1g and 0.03g pentadacanolide are dissolved in 5mL dichloro
In methane, after stirring, add 0.05g3-methyl-1-pentene alkynes-3-alcohol and the catalyst of 0.1mol/L
The dichloromethane solution 100mL of double (double trimethyls are silica-based) amine zinc, stirring is subsequently adding 0.001g
Azodiisobutyronitrile, is sealed in 45 DEG C and reacts 28 hours, terminate reaction with glacial acetic acid, at ice ether
Middle precipitation, filters, is vacuum dried and obtains carbonate polymer.
Mixing 7mL phosphate buffer, 2.4mL glycol monoethyl ether, 0.6mL water, then by 0.1g
Carbonate polymer disperses wherein, stirs, and is eventually adding 5mg ginsenoside Rd, ultrasonic point
After dissipating half an hour, sterilizing, obtain medicine.
Embodiment five
In a nitrogen environment, third heptalactone of 0.1g and 0.05g pentadacanolide are dissolved in 5mL dichloro
In methane, after stirring, add 0.04g3-methyl-1-pentene alkynes-3-alcohol and the catalyst of 0.1mol/L
The dichloromethane solution 100mL of double (double trimethyls are silica-based) amine zinc, stirring is subsequently adding 0.001g
Azodiisobutyronitrile, is sealed in 45 DEG C and reacts 28 hours, terminate reaction with glacial acetic acid, at ice ether
Middle precipitation, filters, is vacuum dried and obtains carbonate polymer.
Mixing 6.5mL phosphate buffer, 2mL glycol monoethyl ether, 1.5mL water, then by 0.1g
Carbonate polymer disperses wherein, stirs, and is eventually adding 3mg ginsenoside Rd, ultrasonic point
After dissipating half an hour, sterilizing, obtain medicine.
Embodiment six
In a nitrogen environment, third heptalactone of 0.1g and 0.05g pentadacanolide are dissolved in 5mL dichloro
In methane, after stirring, add 0.04g3-methyl-1-pentene alkynes-3-alcohol and the catalyst of 0.1mol/L
The dichloromethane solution 100mL of double (double trimethyls are silica-based) amine zinc, stirring is subsequently adding 0.001g
Azodiisobutyronitrile, is sealed in 45 DEG C and reacts 28 hours, terminate reaction with glacial acetic acid, at ice ether
Middle precipitation, filters, is vacuum dried and obtains carbonate polymer.
Mixing 6.5mL phosphate buffer, 2mL glycol monoethyl ether, 1.5mL water, then by 0.1g
Carbonate polymer disperses wherein, stirs, and is eventually adding 2mg ginsenoside Rd, ultrasonic point
After dissipating half an hour, sterilizing, obtain medicine.
Embodiment seven
In a nitrogen environment, third heptalactone of 0.1g and 0.03g pentadacanolide are dissolved in 5mL dichloro
In methane, after stirring, add 0.05g3-methyl-1-pentene alkynes-3-alcohol and the catalyst of 0.1mol/L
The dichloromethane solution 100mL of double (double trimethyls are silica-based) amine zinc, stirring is subsequently adding 0.001g
Azodiisobutyronitrile, is sealed in 45 DEG C and reacts 28 hours, terminate reaction with glacial acetic acid, at ice ether
Middle precipitation, filters, is vacuum dried and obtains carbonate polymer.
Mixing 6.5mL phosphate buffer, 2mL glycol monoethyl ether, 1.5mL water, then by 0.1g
Carbonate polymer disperses wherein, stirs, and is eventually adding 3mg ginsenoside Rd, ultrasonic point
After dissipating half an hour, sterilizing, obtain medicine.
Embodiment eight
In a nitrogen environment, third heptalactone of 0.1g and 0.03g pentadacanolide are dissolved in 5mL dichloro
In methane, after stirring, add 0.05g3-methyl-1-pentene alkynes-3-alcohol and the catalyst of 0.1mol/L
The dichloromethane solution 100mL of double (double trimethyls are silica-based) amine zinc, stirring is subsequently adding 0.001g
Azodiisobutyronitrile, is sealed in 45 DEG C and reacts 28 hours, terminate reaction with glacial acetic acid, at ice ether
Middle precipitation, filters, is vacuum dried and obtains carbonate polymer.
Mixing 6.5mL phosphate buffer, 2mL glycol monoethyl ether, 1.5mL water, then by 0.1g
Carbonate polymer disperses wherein, stirs, and is eventually adding 2mg ginsenoside Rd, ultrasonic point
After dissipating half an hour, sterilizing, obtain medicine.
Embodiment nine toxicity trial
Take the mice 30 of body weight 28 ± 2g, male and female half and half；It is randomly divided into two groups, respectively presses 1mL/20g
Gavage embodiment five, the medicine of embodiment eight, Continuous Observation is the Survival of mice in 30 days, knot
Fruit finds, in 30 days, all mice feeding activities are normal, do not have death, the medicine of the present invention is described
Thing toxicity is the lowest.
Embodiment ten Drug therapy is tested
Take the mice 50 of body weight 35 ± 2g, male and female half and half；Prepare on the left of mice big according to Longa method
Brain medium-sized artery thromboembolism model.With 3% urethane (400mg kg-1) intraperitoneal injection of anesthesia mice, lie on the back solid
Fixed, cervical region unhairing sterilization Posterior midline approach, isolate left common carotid, internal carotid artery and external carotid artery,
Ligation external carotid artery, opens osculum on common carotid artery, by a diameter of 0.1mm of a head end silicone rubber parcel
Silk thread along common carotid artery, be inserted to middle cerebral artery crotch through internal carotid artery to intracranial, insertion depth is about
17mm, ligation internal carotid artery and common carotid artery, fixing silk thread, skin suture.After ischemia 2h, silk thread is drawn
Go out to neck at aortic bifurcation, obtain mouse model.
Dividing five groups at random by 50 mices, for medicine group, matched group, drug component is embodiment one, reality
Execute example four, embodiment six groups, embodiment eight；It is administered according to 7.5mL/Kg, once a day, continuous eight days；
Matched group correspondence is to phosphate buffer.Last is administered latter 2 hours, tests.The brain that each group is corresponding
Infarction size is, matched group, embodiment one, embodiment four, embodiment six groups, embodiment eight are respectively
20.47%, 16.89%, 16.42%, 15.32%, 15.56%.
Embodiment 11: a kind of method preparing treatment cerebrovascular disease medicament, comprises the following steps,
(1) with pentadacanolide and third heptalactone as monomer, carbonate polymer is prepared in polymerization；
Using organic zinc compound as catalyst in this step, using azodiisobutyronitrile as oxidant, with
Methylpentynol is as initiator；In a nitrogen environment, pentadacanolide and in third heptan
Ester is molten in organic solvent, adds initiator and catalyst after stirring, and stirring is subsequently adding oxidant,
Sealing carries out polyreaction, obtains carbonate polymer；Described pentadacanolide and third heptalactone
Mass ratio is 0.3: 1；Polymeric reaction temperature is 45 DEG C, and polymerization time is 28 hours；Organic solvent
For dichloromethane；Catalyst is double (double trimethyls are silica-based) amine zinc, and reaction terminates, with glacial acetic acid eventually
Only reaction, precipitates in ice ether, filters, is vacuum dried and obtains carbonate polymer.
(2) mixed phosphate salt buffer, glycol monoethyl ether, water obtain disperse medium；Described second
The percent by volume of glycol monomethyl ether is 2.0%；
(3) carbonate polymer is added in disperse medium, be stirring evenly and then adding into ginsenoside Rd；
After ultrasonic disperse half an hour, sterilizing, obtain preparation treatment cerebrovascular disease medicine；Radix Ginseng soap in this step
Glycosides Rd is 0.02: 1 with the mass ratio of carbonate polymer.
Should be understood that after having read the disclosure, those skilled in the art can be to this
Bright making various changes or modifications, these equivalent form of values fall within scope defined herein equally.
Claims (10)
1. the method preparing treatment cerebrovascular disease medicament, comprises the following steps,
(1) with pentadacanolide and third heptalactone as monomer, polymerization is prepared carbonic ester and is gathered
Compound；
(2) mixed phosphate salt buffer, glycol monoethyl ether, water obtain disperse medium；
(3) carbonate polymer is added in disperse medium, be stirring evenly and then adding into Radix Ginseng
Saponin Rd；After ultrasonic disperse half an hour, sterilizing, obtain preparation treatment cerebrovascular disease medicine.
The method preparing treatment cerebrovascular disease medicament the most according to claim 1, its
It is characterised by: in step (1), using organic zinc compound as catalyst, with azo two
Isopropyl cyanide is as oxidant, using methylpentynol as initiator.
The most according to claim 2, the method preparing treatment cerebrovascular disease medicament, it is special
Levying and be: in a nitrogen environment, pentadacanolide and third heptalactone are dissolved in organic solvent
In, adding initiator and catalyst after stirring, stirring is subsequently adding oxidant, is sealed into
Row polyreaction, obtains carbonate polymer.
The method preparing treatment cerebrovascular disease medicament the most according to claim 3, its
It is characterised by: the mass ratio of described pentadacanolide and third heptalactone is 0.3～0.5: 1.
The method preparing treatment cerebrovascular disease medicament the most according to claim 3, its
Being characterised by: polymeric reaction temperature is 45 DEG C, polymerization time is 28 hours.
The method preparing treatment cerebrovascular disease medicament the most according to claim 3, its
It is characterised by: organic solvent is dichloromethane；Catalyst is double (double trimethyls are silica-based)
Amine zinc.
The method preparing treatment cerebrovascular disease medicament the most according to claim 3, its
It is characterised by: reaction terminates, terminates reaction with glacial acetic acid, precipitate in ice ether, mistake
Filter, vacuum drying obtain carbonate polymer.
The method preparing treatment cerebrovascular disease medicament the most according to claim 1, its
Be characterised by: in step (2), the percent by volume of described glycol monoethyl ether be 1.2～
2.4%.
The method preparing treatment cerebrovascular disease medicament the most according to claim 1, its
It is characterised by: in step (3), ginsenoside Rd and the mass ratio of carbonate polymer
It is 0.01～0.05: 1.
The method preparing treatment cerebrovascular disease medicament the most according to claim 9, its
It is characterised by: in step (3), ginsenoside Rd and the mass ratio of carbonate polymer
It is 0.02～0.03: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610327364.XA CN105902554A (en) | 2016-05-16 | 2016-05-16 | Method for preparing a medicament for treating cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610327364.XA CN105902554A (en) | 2016-05-16 | 2016-05-16 | Method for preparing a medicament for treating cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105902554A true CN105902554A (en) | 2016-08-31 |
Family
ID=56749419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610327364.XA Pending CN105902554A (en) | 2016-05-16 | 2016-05-16 | Method for preparing a medicament for treating cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105902554A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150018483A1 (en) * | 2013-07-10 | 2015-01-15 | Xerox Corporation | Method for generation of nanoparticles |
| CN104672199A (en) * | 2015-02-13 | 2015-06-03 | 苏州大学 | Double-iodine cyclic carbonate compound and preparation method thereof |
-
2016
- 2016-05-16 CN CN201610327364.XA patent/CN105902554A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150018483A1 (en) * | 2013-07-10 | 2015-01-15 | Xerox Corporation | Method for generation of nanoparticles |
| CN104672199A (en) * | 2015-02-13 | 2015-06-03 | 苏州大学 | Double-iodine cyclic carbonate compound and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张潇: "人参皂苷Rd对大鼠脑缺血后细胞间液生物活性小分子含量的影响", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
| 陈启昌等: "聚碳酸酯合成技术综述", 《化工科技》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2567801C2 (en) | Methods for treating and preventing fatigue | |
| CN108452303A (en) | It is a kind of to carry double medicine nanometer formulations and preparation method thereof | |
| CN105769891B (en) | Low polarity rare ginsenoside mixture and application thereof | |
| CN113663079B (en) | Carrier-free self-assembly nano particle and preparation method and application thereof | |
| WO2012034540A1 (en) | Anti-tumor pharmaceutical composition | |
| US9844564B2 (en) | PVAX copolymer and PVAX microparticles comprising the same | |
| CN114259475A (en) | Preparation and application of near-infrared light activated drug self-delivery nano preparation | |
| CN105902554A (en) | Method for preparing a medicament for treating cerebrovascular diseases | |
| JP2004517961A (en) | Cancer treatment | |
| AU2018348892B2 (en) | Formulation containing A-decarbonized-5a androstane compound for increasing white blood cell and use thereof | |
| CN1164264C (en) | Dispersed general arasaponin tablet and its prepn and application | |
| CN105816426A (en) | Medicine used for treating cerebrovascular disease | |
| CN102836418B (en) | Pingyangmycin polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) temperature-sensitive slow-release gel, as well as preparation method and application of same | |
| CN105560241B (en) | Application, method and pharmaceutical composition of the quinine dihydrochloride in treatment tumour | |
| CN110870913A (en) | Use of amino acid nutrients as vaccine adjuvants and vaccines comprising amino acid nutrients as adjuvants | |
| CN102846668A (en) | Preparation method for nanometer Periplaneta americana | |
| CN106928298A (en) | The structure composition of ring dinucleotides cGAMP derivatives, preparation method and its application in antitumor | |
| WO2023060785A1 (en) | Use of tetramethylpyrazine nitrone derivative in treatment of ischemic stroke | |
| CN113116873B (en) | New use of aloe-emodin as anti-mast cell activator | |
| RU2706346C1 (en) | Method of treating operable gastric adenocarcinoma | |
| CN110721310B (en) | Application of pharmaceutical composition in preparation of medicine for treating acute hemorrhagic brain injury | |
| CN106924251B (en) | It is a kind of for treating the pharmaceutical composition and its application of glioma | |
| CN106822099A (en) | The medicinal composition for injections that vitamin C acts synergistically with benzenesulfonamide compounds | |
| CN105949071A (en) | Compound for treating cardiovascular disease and medicine based on compound | |
| CN102058582B (en) | Application of indole-2,3-diketone to preparing medicament for resisting aphronesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160831 |